ITI Pharma & Healthcare Fund - IDCW - Direct Plan

Other Plans and Options
  • 1.8 %Nav, as on 13-08-2025

  • Previous Nav

  • Net Change on 13-08-2025

  • PersonalFN Rating

  • Assets (Cr.)

  • Expense Ratio

Fund Overview IDCW | Direct Plan

  • Fund House

  • Launch Date

  • Benchmark

  • Minimum Investment (₹)

  • Minimum Addl Investment (₹)

  • Exit Load (%)

  • Minimum SIP Investment (₹)

  • Minimum STP Investment (₹)

  • Minimum SWP Investment (₹)

  • 52 Week Low Nav (₹)

  • 52 Week Low Nav Date

  • 52 Week High Nav (₹)

  • 52 Week High Nav Date

Fund Objective

The investment objective of the scheme is to seek to generate long term capital appreciation throughinvesting in equity and equity related securities of companies engaged in Pharma and Healthcare.However, there can be no assurance or guarantee that the investment objective of the Scheme would be achieved.

Fund Performance

Scheme Name 1-Month Return (%) 3-Month Return (%) 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Since Inception
NIFTY 50 - TRI N/A N/A N/A N/A N/A N/A
Nifty Healthcare Index - TRI N/A N/A N/A N/A N/A N/A

Returns upto 1 year is Absolute, and above 1 year are Compounded Annualised

Peer Fund Comparison

Scheme Name Launch Date Ratings 1-Year Return (%) 3-Year Return (%) 5-Year Return (%) Expense Ratio (%) Assets (Cr.)
NIPPON INDIA PHARMA FUND - DIRECT Plan - IDCW Option Jan 01, 2013 2.91 23.30 19.29 0.89 8,736.57
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund - Direct Plan - IDCW Option Jul 13, 2018 9.45 28.39 22.07 1.04 6,103.96
SBI Healthcare Opportunities Fund - Direct Plan - Income Distribution cum Capital Withdrawal Option (IDCW) Jan 01, 2013 11.51 27.64 21.28 0.91 4,026.55
Mirae Asset Healthcare Fund Direct IDCW Jul 02, 2018 5.29 22.67 20.15 0.48 2,908.21
TATA India Pharma & Health Care Fund Direct Plan - Payout of Income Distribution cum capital withdrawal option Dec 28, 2015 4.88 24.98 20.33 0.61 1,339

Fund Holdings as on 31-July-2025

  • Sun Pharmaceutical Industries Limited

  • Divi's Laboratories Limited

  • Max Healthcare Institute Limited

  • Apollo Hospitals Enterprise Limited

  • Cohance Lifesciences Limited

  • Torrent Pharmaceuticals Limited

  • Aurobindo Pharma Limited

  • Fortis Healthcare Limited

  • Lupin Limited

  • Aster DM Healthcare Limited

  • Mankind Pharma Limited

  • Wockhardt Limited

  • Alkem Laboratories Limited

  • Abbott India Limited

  • Neuland Laboratories Limited

  • Sumitomo Chemical India Limited

  • Healthcare Global Enterprises Limited

  • Vijaya Diagnostic Centre Limited

  • FDC Limited

  • Granules India Limited

  • Laurus Labs Limited

  • Rainbow Childrens Medicare Limited

  • Net Receivables / (Payables)

  • Sagility India Limited

  • Dr. Reddy's Laboratories Limited

  • Orchid Pharma Limited

  • Shilpa Medicare Limited

  • GlaxoSmithKline Pharmaceuticals Limited

  • Onesource Specialty Pharma Limited

  • Navin Fluorine International Limited

  • Supriya Lifescience Limited

  • Strides Pharma Science Limited

  • Cipla Limited

  • IPCA Laboratories Limited

  • SRF Limited

  • Caplin Point Laboratories Limited

  • Linde India Limited

  • Standard Glass Lining Technology Ltd

  • Sai Life Sciences Limited

  • Advanced Enzyme Technologies Limited

  • Biocon Limited

  • SBI Life Insurance Company Limited

  • Glenmark Pharmaceuticals Limited

  • UPL Limited

  • Syngene International Limited

  • TTK Healthcare Limited

View More

  • Pharmaceuticals & Drugs

  • Hospital & Healthcare Services

  • Pesticides & Agrochemicals

  • Chemicals

  • Business Support

  • Miscellaneous

  • Industrial Gases & Fuels

  • Engineering - Industrial Equipments

  • Insurance

  • Diversified

View More

Fund Manager

  • Cash

  • Equity

View More

About ITI Pharma & Healthcare Fund

Scheme Analysis

ITI Pharma & Healthcare Fund is a Equity - Sectoral Fund - Pharma & Health Care fund and belongs to ITI Mutual Fund. It was launched on 08-Nov-2021 and currently has an AUM of ₹235.68 crore. ITI Pharma & Healthcare Fund is benchmarked against NIFTY 50 - TRI as primary index and Nifty Healthcare Index - TRI as secondary index.

The NAV of ITI Pharma & Healthcare Fund ended up ₹0.31(1.8%)yesterday to ₹17.7637.

Among its top 3 holdings the fund has exposure to Sun Pharmaceutical Industries Limited, and

The ITI Pharma & Healthcare Fund is managed by Dhimant Shah and Rohan Korde.

Fund House Contact

ITI House, 36, R K Shirodkar Marg, Parel Mumbai - 400 012

022-69153500
mfassist@itiorg.com
www.itiamc.com